Ferring   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Saint-prex Switzerland (1950)
Status: No NME R&D (1950)

Organization Overview

First Clinical Trial
1996
NCT01538784
First Marketed Drug
1973
recombinant human choriogonadotropin alfa (Ovidrel)
First NDA Approval
1973
recombinant human choriogonadotropin alfa (Ovidrel)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Ferríng Pharmaceuticals | FERRING | Ferring Arzneimittel GmbH | Ferring Holding Ltd. | Ferring Pharmaceuticals | Ferring Pharmaceuticals Korea, Ltd. | FERRING PHARMS INC | Ferring SAU

Active Ingredients

Marketed Drugs (16)

citric acid (2012)

corticorelin ovine triflutate (acthrel) (1996 NDA)

degarelix acetate (firmagon) (2008 NDA)

desmopressin (ddavp) (1978 NDA)

dinoprostone (prostin e2) (1995)

gonadorelin (factrel) (1989)

lutropin alpha (luveris) (1997)

magnesium oxide (2012)

progesterone (progestasert) (2007)

protirelin (thypinone) (1978)

recombinant human choriogonadotropin alfa (Ovidrel) (1973 NDA)

secretin human (chirhostim) (NDA)

sodium picosulfate (2012 NDA)

somatropin (protropin) (1995)

tranexamic acid (cyklokapron) (2009)

urofollitropin (metrodin) (2002)

Drugs in Phase 4 Trials (22)

bisacodyl (Halflytely) (3 trials)

cetrorelix (cetrotide) (3 trials)

citric acid (4 trials)

degarelix acetate (firmagon) (57 trials)

desmopressin (ddavp) (23 trials)

dinoprostone (prostin e2) (7 trials)

follitropin alfa (16 trials)

follitropin beta (4 trials)

ganirelix (2 trials)

goserelin (zoladex) (8 trials)

hyaluronic acid (3 trials)

leuprolide (lupron) (10 trials)

mannitol (1 trial)

Menotropin (3 trials)

oxytocin (syntocinon) (2 trials)

progesterone (progestasert) (9 trials)

recombinant human choriogonadotropin alfa (Ovidrel) (4 trials)

sodium picosulfate (10 trials)

sodium sulfate (1 trial)

tranexamic acid (cyklokapron) (5 trials)

trimagnesium dicitrate (5 trials)

urofollitropin (metrodin) (16 trials)

Drugs in Phase 3 Trials (36)

Key: Ferring (35) Acquired (1)

aminosalicylic acid (Paser) (1 trial)

bicalutamide (casodex) (4 trials)

bifidobacterium breve (2 trials)

bifidobacterium infantis (2 trials)

bifidobacterium longum (2 trials)

budesonide (rhinocort) (3 trials)

carbetocin (1 trial)

clomifene (clomid) (2 trials)

docusate sodium (1 trial)

elobixibat (4 trials)

ergonovine (1 trial)

fe 999049 (5 trials)

fe 999169 (1 trial)

fe 999913 (1 trial)

follitropin delta (7 trials)

glycerin (2 trials)

gonadorelin (factrel) (3 trials)

gonapeptyl (1 trial)

Lactobacillus acidophilus (2 trials)

lactobacillus casei (2 trials)

lactobacillus delbrueckii (2 trials)

lactobacillus plantarum (2 trials)

macrogol (1 trial)

magnesium oxide (2 trials)

mesalamine (rowasa) (9 trials)

mesalazine (1 trial)

misoprostol (cytotec) (8 trials)

polyethylene glycol (4 trials)

potassium chloride (klor-con) (1 trial)

rbx2660 (5 trials)

selepressin (3 trials)

somatropin (protropin) (6 trials)

sorbitol (1 trial)

streptococcus salivarius (2 trials)

testosterone (delatestryl) (5 trials)

vsl #3 (2 trials)

Drugs in Phase 2 Trials (28)

Key: Ferring (18) Acquired (10)

abiraterone (zytiga) (1 trial)

aeg33773 (1 trial)

aeg35156 (7 trials)

barusiban (4 trials)

cholestyramine (questran) (1 trial)

decitabine (dacogen) (1 trial)

docetaxel (taxotere) (1 trial)

estradiol (progynon depot) (1 trial)

fe 201836 (1 trial)

fe 992097 (1 trial)

genistein (1 trial)

human fecal microbiota (1 trial)

ipilimumab (yervoy) (1 trial)

isoquercetin (1 trial)

lidocaine (xylocaine) (1 trial)

merotocin (1 trial)

norethindrone (1 trial)

polyethylene glycol 3350 (colyte) (1 trial)

quinagolide (3 trials)

rbx7455 (3 trials)

ringer's lactate (1 trial)

semapimod (5 trials)

sodium chloride (1 trial)

sorafenib (nexavar) (1 trial)

terlipressin (1 trial)

tolterodine (detrol) (1 trial)

tractocile (1 trial)

xiap antisense (1 trial)

Drugs in Phase 1 Trials (5)

bms-986218 (1 trial)

fe 204205 (1 trial)

netazepide (4 trials)

omeprazole (prilosec) (1 trial)

ranitidine (zantac) (1 trial)

Drugs in Other Trials (6)

aloe vera (1 trial)

menopausal gonadotropin (5 trials)

receptal (1 trial)

sodium dichloroacetate (1 trial)

triptorelin (Trelstar) (1 trial)

vitamin q (2 trials)

Indications

Approved Indications


 

Cushing Syndrome

Diabetes Insipidus, Neurogenic

Exocrine Pancreatic Insufficiency

Gastrinoma

Hemophilia A

Hemorrhage

Pancreatic Diseases

Prostatic Neoplasms

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenomyosis (Phase 2)

Amenorrhea (Phase 3)

Anovulation (Phase 3)

Aortic Valve Stenosis (Phase 4)

Cardiovascular Diseases (Phase 4)

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Constipation (Phase 3)

Constriction, Pathologic (Phase 4)

Crohn Disease (Phase 3)

Diabetes Insipidus (Phase 3)

Diabetes Insipidus, Neurogenic (Phase 3)

Diarrhea (Phase 3)

Dwarfism, Pituitary (Phase 3)

Endocrine System Diseases (Phase 3)

Endometrial Hyperplasia (Phase 2)

Endometrial Neoplasms (Phase 2)

Endometriosis (Phase 2)

Enuresis (Phase 4)

Esophagitis (Phase 1)

Esophagitis, Peptic (Phase 1)

Gonadal Dysgenesis (Phase 3)

Hemorrhage (Phase 3)

Hepatorenal Syndrome (Phase 2)

Hyperphagia (Phase 2)

Hyperplasia (Phase 2)

Hypersensitivity (Phase 2)

Hypertension (Phase 1)

Hypertension, Portal (Phase 1)

Hypogonadism (Phase 3)

Hyponatremia (Phase 4)

Infertility (Phase 4)

Infertility, Female (Phase 4)

Lower Urinary Tract Symptoms (Phase 2)

Menorrhagia (Phase 4)

Nocturia (Phase 3)

Nocturnal Enuresis (Phase 4)

Obstetric Labor, Premature (Phase 2)

Osteoarthritis (Phase 4)

Osteoarthritis, Knee (Phase 4)

Ovarian Hyperstimulation Syndrome (Phase 2)

Polycystic Ovary Syndrome (Phase 4)

Polyuria (Phase 3)

Postpartum Hemorrhage (Phase 3)

Prader-Willi Syndrome (Phase 2)

Premature Birth (Phase 2)

Prostatic Hyperplasia (Phase 2)

Prostatic Neoplasms (Phase 4)

Shock (Phase 3)

Shock, Septic (Phase 3)

Syndrome (Phase 4)

Turner Syndrome (Phase 3)

Ulcer (Phase 3)

Urinary Bladder, Overactive (Phase 2)

Urinary Incontinence (Phase 4)

von Willebrand Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 244
  • # of Trial APIs: 97